Genomic Health, Inc.
GHDX
GHDX was delisted on the 7th of November, 2019.
134 hedge funds and large institutions have $870M invested in Genomic Health, Inc. in 2016 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 53 increasing their positions, 42 reducing their positions, and 10 closing their positions.
40% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 10
26% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 42
13% more capital invested
Capital invested by funds: $772M → $870M (+$97.6M)
3% more funds holding
Funds holding: 130 → 134 (+4)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
100% less call options, than puts
Call options by funds: $1K | Put options by funds: $220K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
+$13.1M |
| 2 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$8.11M |
| 3 |
Charles Schwab
San Francisco,
California
|
+$6.83M |
| 4 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$3.18M |
| 5 |
Renaissance Technologies
New York
|
+$3.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$15.9M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$7.1M |
| 3 |
BC
Broadfin Capital
New York
|
-$7M |
| 4 |
TGHSA
TPG Group Holdings (SBS) Advisors
Fort Worth,
Texas
|
-$6.74M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.21M |
GHDX Hedge Fund Activity: Q3 2016 in Review
134 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Genomic Health, Inc. (GHDX) for Q3 2016, worth a combined $870M — up 13% from $772M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new GHDX positions and 10 closed out — a net gain of 4 holders — while 53 added to existing stakes and 42 trimmed.
The largest buyer was Columbia Wanger Asset Management, opening a new position worth an estimated $13.1M. The largest seller was Baillie Gifford & Co, cutting an estimated $15.9M.
- 134 institutional investors held Genomic Health, Inc. (GHDX) as of Q3 2016, up from 130 in Q2 2016.
- Funds reported $870M of Genomic Health, Inc. stock for Q3 2016, up 13% quarter-over-quarter.
- 14 funds opened new Genomic Health, Inc. positions in Q3 2016 and 10 closed out, a net change of +4 holders.
- The largest Genomic Health, Inc. buyer in Q3 2016 was Columbia Wanger Asset Management, an estimated $13.1M added.
- The largest Genomic Health, Inc. seller in Q3 2016 was Baillie Gifford & Co, an estimated $15.9M sold.
Based on aggregated 13F filings for Q3 2016.